The recent data demonstrating that vaccines constituted by mutation-derived CD4+/CD8+ T cell neoepitopes induce anti-tumor immune responses in both preclinical and clinical settings (20, 21), had prompted us to test whether the unique properties of OMVs could be exploited in cancer immunotherapy. The gene discussed is CD8A; the disease is neoplasm.